Monday, January 10, 2022 5:51:18 PM
I dunno where you are in stock holding amount or value but this right here is the bottom. If they screw up it will become $2.60 to 0
I do think this is baseline and we are churning with a lot more purchase than sell.
I do think this is baseline and we are churning with a lot more purchase than sell.
Recent OCGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 01:26:46 AM
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease • GlobeNewswire Inc. • 04/01/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 04:02:11 PM
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 03/24/2026 11:45:00 AM
- Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy • GlobeNewswire Inc. • 03/23/2026 11:02:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 12:00:18 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:27:38 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2026 05:23:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 04:38:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 04:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 04:07:26 PM
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/04/2026 01:15:00 PM
- Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa • GlobeNewswire Inc. • 03/02/2026 12:02:00 PM
- Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/18/2026 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:59:25 PM
- Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer • GlobeNewswire Inc. • 02/09/2026 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 01:12:02 PM
- Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock • GlobeNewswire Inc. • 01/23/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 10:29:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/21/2026 10:27:56 PM
- Ocugen shares slide after company prices $22.5 million equity raise • IH Market News • 01/21/2026 03:35:56 PM
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock • GlobeNewswire Inc. • 01/21/2026 01:32:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 01:31:02 PM
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 01/15/2026 01:15:00 PM
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data • GlobeNewswire Inc. • 01/13/2026 12:00:00 PM
